BCL2 and pancreatic neoplasm: One example would be Navitoclax (ABT‐263), which exerts its senolytic activity by targeting Bcl‐2 anti‐apoptotic proteins, and when administered in combination with gemcitabine, it was demonstrated to kill gemcitabine‐resistant and senescent‐like pancreatic cancer cells [50].